Why Insulin Never Reaches the Liver

Episode notes

Send us Fan Mail The liver is the only organ in the body that can release stored glucose to prevent low blood sugar. So why has injected insulin never been able to reach it? In this clip from our episode “Finding a Solution for GLP-1 Side Effects”, host David E. Williams and Bob Geho, Founder and CEO of Diasome, break down the biological gap at the heart of diabetes treatment and how a father's decades of research into liver-targeted insulin delivery became the founding idea behind Diasome. Listen to the full episode here ️️ABOUT BOB GEHO Bob Geho is the Chief Executive Officer of Diasome Pharmaceuticals, a clinical-stage biopharmaceutical company developing portal-hepatic -targeted therapies designed to act at the source of metabolic regulation. Under his leadership, Diasome is advancing its proprietary Hepatocyte-Directed Vesicle (HDV) platform, which targets liver hepatocytes and the portal hepatic region, where metabolic control is centered. The company's lead clinical program, HDV-Insulin, applies this approach to insulin therapy - grounded in the principle that therapies working with the body's natural physiology may produce meaningfully better outcomes.

• GLP-1s May Reduce Cancer Progression16 / 100
• The Business & Science Behind the GLP-1 Boom44 / 100
• Why We Can Never Have Enough Doctors40 / 100
• The Future of Medicine Is Already Here w/ Bertalan Mesko, The Medical Futurist Institute
• Targeting the Root Causes of Metabolic Disease w/ Bob Geho, Founder & CEO, Diasome